Oncology Arch, Inc. Clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 antibody therapies, today announced a successful $50 million Series B funding The Company plans to use the proceeds from this funding to advance the ongoing Phase 1 clinical trial of its AO-176 anti-CD47 antibody in selected solid tumors and its pipeline.
This financing included existing investors from Arch Oncology, RiverVest Venture Partners, Roche Venture Fund and 3×5 Partners, and was led by new investor Lightchain (Scottrade Founder and former CEO Rodger Riney’s family office)
“Our investors share our commitment to the exciting work we are doing to develop best-in-class antibodies to improve treatment options for cancer patients,” said Julie M. Oh, Cherrington, Ph D. D. , President and Chief Executive Officer of Arch Oncology; “This funding supports our ongoing Phase 1 clinical trial of AO-176, our highly differentiated anti-CD47 antibody, as we continue to dose patients. In addition, these revenues allow us to advance our discovery-stage pipeline. With the support of our investors and the hard work of our experienced team, we look forward to developing new cancer treatment options for patients. “That’s right.
“The Arch Oncology team under Julie’s leadership over the past year has successfully implemented plans to move AO-176 from the laboratory, through IND submission, and to the clinic,” said John McKearn, Ph.D. D. D. , Managing Director, RiverVest Venture Partners and Chairman of the Board of Arch Oncology; “We believe that AO-176 has the best-in-class profile among agents in anti-CD47 space, and we are excited to see the progress made by the pipeline. “That’s right.
On the Arch Oncology
Oncology Arch, Inc. The privately-held, clinical-stage immuno-oncology company focuses on the discovery and development of best-in-class antibody therapy for the treatment of cancer patients. The company’s next-generation anti-CD47 antibodies are highly differentiated, with the potential to improve the safety and efficacy profile relative to other agents in this class. Arch Oncology’s lead product candidate, AO-176, is in a Phase 1 clinical trial for the treatment of selected solid tumor patients. In addition, the Company is implementing a number of pipeline programs, including anti-signal regulatory protein (SIRP) antibodies. Arch Oncology’s leadership team has already successfully developed new drugs for patients and is supported by leading investors, including RiverVest Venture Partners, Roche Venture Fund, 3×5 RiverVest Partners II-B and Lightchain. Please visit www for more information. Archoncology: Come on,
Please note that this piece of work originally appeared in English at https://www.vcnewsdaily.com/Arch%20Oncology/venture-funding.php. As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at contact@investocracy.co
